BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 23811754)

  • 1. Antitumor effects of Endostar on non-Hodgkin's lymphoma by regulating endothelial progenitor cells through protein kinase B-dependent pathway.
    Yu D; Wu H; Yang B; Yang K; Liu H; Wu G
    Acta Biochim Biophys Sin (Shanghai); 2013 Sep; 45(9):742-8. PubMed ID: 23811754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells.
    Ling Y; Yang Y; Lu N; You QD; Wang S; Gao Y; Chen Y; Guo QL
    Biochem Biophys Res Commun; 2007 Sep; 361(1):79-84. PubMed ID: 17644065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endostar attenuates melanoma tumor growth via its interruption of b-FGF mediated angiogenesis.
    Xiao L; Yang S; Hao J; Yuan X; Luo W; Jiang L; Hu Y; Fu Z; Zhang Y; Zou C
    Cancer Lett; 2015 Apr; 359(1):148-54. PubMed ID: 25597785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endostar, a modified recombinant human endostatin, exhibits synergistic effects with dexamethasone on angiogenesis and hepatoma growth.
    Li XQ; Shang BY; Wang DC; Zhang SH; Wu SY; Zhen YS
    Cancer Lett; 2011 Feb; 301(2):212-20. PubMed ID: 21216091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumoral effect of arsenic compound, sodium metaarsenite (KML001), in non-Hodgkin's lymphoma: an in vitro and in vivo study.
    Yoon JS; Hwang DW; Kim ES; Kim JS; Kim S; Chung HJ; Lee SK; Yi JH; Uhm J; Won YW; Park BB; Choi JH; Lee YY
    Invest New Drugs; 2016 Feb; 34(1):1-14. PubMed ID: 26581399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human recombinant endostatin Endostar attenuates hepatic sinusoidal endothelial cell capillarization in CCl4‑induced fibrosis in mice.
    You Q; Kong LJ; Li FD; Wang HY; Liu DG; Pei FH; Song JT; Xu J; Chen J
    Mol Med Rep; 2015 Oct; 12(4):5594-600. PubMed ID: 26239504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CS2164 exerts an antitumor effect against human Non-Hodgkin's lymphomas in vitro and in vivo.
    Deng M; Shi Y; Chen K; Zhao H; Wang Y; Xie S; Zhao J; Luo Y; Fang Z; Fan Y; Xu B
    Exp Cell Res; 2018 Aug; 369(2):356-362. PubMed ID: 29864401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic antiangiogenic activity of tetrandrine combined with Endostar on the human umbilical vein endothelial cell model.
    Qian X; Yan B; Zhou X; Xie L; Wei J; Li R; Yu L; Liu B
    Cancer Biother Radiopharm; 2013 Jun; 28(5):385-90. PubMed ID: 23682584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Observation of the antitumor effect of endostar combined with docetaxel under different administration sequences].
    Yuan J; Wu CW; Liu ZJ; Wei XY; Li K
    Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):580-5. PubMed ID: 21122408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endostar inhibits hypoxia-induced cell proliferation and migration via the hypoxia-inducible factor-1α/vascular endothelial growth factor pathway in vitro.
    Lin K; Ye P; Liu J; He F; Xu W
    Mol Med Rep; 2015 May; 11(5):3780-5. PubMed ID: 25543905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of ADAM12 contributes to accelerated cell proliferation and cell adhesion-mediated drug resistance (CAM-DR) in Non-Hodgkin's Lymphoma.
    Yin H; Zhong F; Ouyang Y; Wang Q; Ding L; He S
    Hematology; 2017 Oct; 22(9):527-535. PubMed ID: 28395594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endostar, a recently introduced recombinant human endostatin, inhibits proliferation and migration through regulating growth factors, adhesion factors and inflammatory mediators in choroid-retinal endothelial cells.
    Xu W; Ye P; Li Z; Shi J; Wang W; Yao K
    Mol Biol (Mosk); 2010; 44(4):664-70. PubMed ID: 20873226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel methionine aminopeptidase-2 inhibitor, PPI-2458, inhibits non-Hodgkin's lymphoma cell proliferation in vitro and in vivo.
    Cooper AC; Karp RM; Clark EJ; Taghizadeh NR; Hoyt JG; Labenski MT; Murray MJ; Hannig G; Westlin WF; Thompson CD
    Clin Cancer Res; 2006 Apr; 12(8):2583-90. PubMed ID: 16638869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor anti-angiogenic effect and mechanism of action of delta-tocotrienol.
    Shibata A; Nakagawa K; Sookwong P; Tsuzuki T; Oikawa S; Miyazawa T
    Biochem Pharmacol; 2008 Aug; 76(3):330-9. PubMed ID: 18599020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects.
    Maffucci T; Piccolo E; Cumashi A; Iezzi M; Riley AM; Saiardi A; Godage HY; Rossi C; Broggini M; Iacobelli S; Potter BV; Innocenti P; Falasca M
    Cancer Res; 2005 Sep; 65(18):8339-49. PubMed ID: 16166311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma.
    Lewis TS; McCormick RS; Emmerton K; Lau JT; Yu SF; McEarchern JA; Grewal IS; Law CL
    Clin Cancer Res; 2011 Jul; 17(14):4672-81. PubMed ID: 21610152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Endostar reduces the growth and metastasis by inhibiting angiogenesis and lymphangiogenesis in nude mouse models of human cervical cancer].
    Jia YT; Li ZX; Liu M; Chen SA; Zhang L; Wang YD
    Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):254-7. PubMed ID: 19615276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apatinib exerts anti-tumor activity to non-Hodgkin lymphoma by inhibition of the Ras pathway.
    Wang Y; Deng M; Chen Q; Li Y; Guo X; Shi P; He L; Xie S; Yu L; Zhang H; Xu B
    Eur J Pharmacol; 2019 Jan; 843():145-153. PubMed ID: 30423319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
    Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
    Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
    Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
    Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.